$JAGX: Huge $38M Licensing Deal + Investor Summit Update !

There has been a lot of movement around Jaguar Health ($JAGX) this week, and if you haven't been watching the 8-Ks, you might have missed the scale of what’s happening. 📢 The Big News: $38 Million Licensing Deal: Jaguar Health just entered into a massive exclusive U.S. license agreement with Future Pak (and Woodward Specialty) for their flagship products, Mytesi and Canalevia-CA1. • Cash Injection: Jaguar receives an $18 million upfront payment ($16M at closing). • Milestones: They are eligible for up to $20 million in additional regulatory and commercial milestones. • The Strategy: Jaguar stays the manufacturer while Future Pak handles the heavy lifting for U.S. commercialization. This is a massive move to offload marketing costs while keeping the production revenue. 🎤 Lytham Partners Investor Summit (Jan 15-16) Management is presenting right now (Jan 15-16) at the Lytham Partners Healthcare Investor Summit. They are discussing "near-term catalysts," which likely includes: • Crofelemer Clinical Trials: Updates on the Phase 3 OnTarget study for chemotherapy-induced overactive bowel (CIOB). • Rare Disease Pipeline: Progress on Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS). 📉 Price Action & Technicals • Volatility: The stock has seen heavy volume this week, swinging between $0.74 and $1.14. • Capital Structure: They recently closed a $350k note for working capital, showing they are aggressively fueling operations as they await these trial results. • Sentiment: Short interest has ticked up slightly, but with the $18M cash infusion, the "bankruptcy risk" narrative just took a major hit. Personal Take: JAGX has been a roller coaster for years, but an $18M upfront payment is one of the most significant non-dilutive funding events they’ve had in a long time. If they can show progress on the Phase 3 data during the summit, we might finally see a sustained trend reversal. Are you holding through the summit or waiting for the Phase 3 data? Disclaimer: Not financial advice. Do your own DD.